Critical evaluation of pathogenic factors of primary biliary cirrhosis
Abstract
The aim of review. Primary biliary cirrhosis (PBC) is related to the group of autoimmune cholestasisassociated liver diseases. In the last years prevalence of PBC increased considerably, especially – in Northern European countries. Despite of sufficient progress in studying of main pathophysiological mechanisms of PBC, etiology of disease remains obscure. There was a task to fill these gaps to some extent.
Key points. Etiological factors increasing risk of PBC development include genetic factors, immunologic disorders, and environmental features. Thus the contribution of each of the mentioned groups of factors, at least, partly is determined by demographic, ethnic and geographical features.
Conclusion. Detection of risk factors and the possible PBC causes allows to develop additional treatment approaches, and define new PBC markers, increase rate of early stage diagnostics.
About the Authors
A. F. Sheptulina
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
M. V. Mayevskaya
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Аутоиммунные заболевания печени в практике клинициста / Под ред. Ивашкина В.Т., Буеверова А.О. – М.: Изд. Дом «М-Вести», 2001. – 32 с.
2. Аутоиммунные заболевания печени и перекрестный синдром / Ульрих Лейшнер: Пер. с нем. – Шептулин А.А. – М.: Анахарсис, 2005. – 54 с.
3. Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. Ивашкина В.Т. – 2-е изд. – М.: Изд. Дом «М-Вести», 2005. – 165 с.
4. Ивашкин В.Т. Иммунный гомеостаз и иммунные заболевания печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 3. – С. 4–12.
5. Ивашкин В.Т. Механизмы иммунной толерантности и патологии печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 2. – С. 8–13.
6. Ивашкин В.Т. Основные понятия и положения фундаментальной иммунологии // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2008. – Т. 18, № 4. – С. 4–13.
7. Ивашкин В.Т. Ядерные рецепторы и патология печени Часть 2-я // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – Т. 20, № 4. – С. 7–15.
8. Кузнецова Е.Л., Широкова Е.Н. Гепатобилиарные транспортеры (ОАТР2 и BSEP) в ткани печени пациентов с холестатическими заболеваниями печени на фоне проводимой терапии // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2007. – Т. 17, № 2. – С. 28–34.
9. Холестаз: Руководство для врачей / Под ред. Ивашкина В.Т., Широковой Е.Н. – М.: СИМК, 2012. – 37 с.
10. Широкова Е.Н., Золотаревский В.Б. Первичный билиарный цирроз // Болезни печени и желчевыводящих путей / Под ред. Ивашкина В.Т. – М.: Изд. Дом «М-Вести», 2002. – С. 190–201.
11. Abdulkarim A.S., Petrovic L.M., Kim W.R. et al. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumonia? // J. Hepatol. – 2004. – Vol. 40, N 3. – P. 380–384.
12. Barzilai O., Ram M., Shoenfeld Y. Viral infection can induce the production of autoantibodies // Curr. Opin. Rheumatol. – 2007. – Vol. 19, N 6. – Р. 636–43.
13. Barzilai O., Sherer Y., Ram M. et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report // Ann. N. Y. Acad. Sci. – 2007. – Vol. 1108 – Р. 567–577.
14. Bogdanos D.P., Baum H., Grasso A. et al. Microbial mimics are major targets of cross reactivity with human pyruvate dehydrogense in primary biliary cirrhosis // J. Hepatol. – 2004. – Vol. 40, N 1. – Р. 31–39.
15. Bogdanos D.P., Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis // Clin. Chim. Acta. – 2011. – Vol. 412, N 7–8. – Р. 502–512.
16. Boomkens S.Y., de Rave S., Pot R.G. et al. The role of Helicobacter spp. In the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis // FEMS Immunol. Med. Microbiol. – 2005. – Vol. 44. – Р. 221– 225.
17. Chao-Jun Hu, Guang Song, Wei Huang et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays // Mol. Cell. Proteomics. – 2012. – Vol. 11, N 9. – Р. 669–680.
18. Corpechot C., Chretien Y., Chazouilleres O., Poupon R. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis // J. Hepatol. – 2010. – Vol. 53, N 1. – Р. 62–69.
19. Daniel S. Smyk, Eirini I. Rigopoulou, Luigi Muratori et al. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis // Ann. Hepatol. – 2012. – Vol. 11, N 1. – Р. 7–14.
20. Fritzler M.J., Rattner J.B., Luft L.M. et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F // Autoimmun. Rev. – 2011. – Vol. 10, N 4. – Р. 194–200.
21. Gershwin M.E., Mackay I.R. The Causes of Primary Biliary Cirrhosis: Convenient and Inconvenient Truths // Hepatology. – 2008. – Vol. 47, N 2. – Р. 737–745.
22. Gershwin M.E., Selmi C., Worman H.J. et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients // Hepatology. – 2005. – Vol. 42, N 6. – P.1194–1202.
23. Howel D., Fischbacher C.M., Bhopal R.S. et al. An exploratory population-based case-control study of primary biliary cirrhosis // Hepatology. – 2000. – Vol. 31. – Р. 1055–1060.
24. Jochen Mattner, Javid P. Mohammed. Autoimmune disease triggered by infection with alphaproteobacteria // Expert. Rev. Clin. Immunol. – 2009. – Vol. 5, N 4. – Р. 369–379.
25. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis // N. Engl. J. Med. – 2005. – Vol. 353, N 12. – Р. 1261–1273.
26. Kita H., Matsumura S., He X.S. et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis // J. Clin. Invest. – 2002. – Vol. 109. – Р. 1231–1240.
27. Kyung-Ah Kim, Sook-Hyang Jeong. The diagnosis and treatment of primary biliary cirrhosis // Korean J. Hepatol. – 2011. – Vol. 17, N 3. – Р. 173–179.
28. Lindor K.D., Gershwin M.E., Poupon R. et al. Primary biliary cirrhosis // Hepatology. – 2009. – Vol. 50, N 1.
29. – Р. 291–308.
30. Mayo M.J. Natural history of primary biliary cirrhosis // Clin. Liver Dis. – 2008. – Vol. 12. – N 2. – Р. 277–288.
31. Morshed A., Nishioka M., Saito I. et al. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients // Gastroenterologia Japonica. – 1992. – Vol. 27, N 6. – P. 751–758.
32. Muratori L., Granito A., Muratori P. et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value // Clin. Liver Dis. – 2008. – Vol. 12. – Р. 261–276.
33. Nancy Agmon-Levin, Bat-sheva Porat Katz, Yehuda Shoenfeld. Infection and primary biliary cirrhosis // IMAJ. – 2009. – Vol. 12. – Р. 112–115.
34. Oertelt S., Lian Z.X., Cheng C.M. et al. Antimitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice // J. Immunol. – 2006. – Vol. 177, N 3. – Р. 1655–1660.
35. Olafsson S., Gudjonsson H., Selmi C. et al. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives // Am. J. Gastroenterol. – 2004. – Vol. 99, N 11. – Р. 2143–2146.
36. Pan Zhao, Yukun Han. Low incidence of positive smooth muscle antibody and high incidence of isolated IgM elevation in Chinese patients with autoimmune hepatitis and primary biliary cirrhosis overlap syndrome: a retrospective study // BMC Gastroenterology. – 2012. – Vol. 12, N 1. – Р. 1–4.
37. Parikh-Patel A., Gold E.B., Worman H. et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States // Hepatology. – 2001. – Vol. 33, N 1. – Р. 16–21.
38. Prince M.I., Ducker S.J., James O.F. Case-control study of risk factors for primary biliary cirrhosis in two United Kingdom populations // Gut. – 2010. – Vol. 59. – Р. 508–12.
39. Roman Riegera, M. Eric Gershwina. The X and Why of xenobiotics in primary biliary cirrhosis // J. Autoimmun. – 2007. – Vol. 8, N 2–3. – P.76–84.
40. Selmi C., Balkwill D.L., Invernizzi P. et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium // Hepatology. – 2003. – Vol. 38. – Р. 1250–1257.
41. Selmi C., Invernizzi P., Zuin M. et al. Genes and (auto) immunity in primary biliary cirrhosis // Genes Immun. – 2005. – Vol. 6. – Р. 543–556.
42. Selmi C., Zuin M., Gershwin M.E. The unfinished business of primary biliary cirrhosis // J. Hepatol. – 2008. – Vol. 49, N 3. – Р. 451–460.
43. Toussirot É., Roudier J. Epstein-Barr virus in autoimmune diseases // Best Pract. Res. Clin. Rheumatol. – 2008. – Vol. 22, N 5. – Р. 883–896.
44. Vilagut L., Pares A., Vinas O. et al. Antibodies to mycobacterial 65 kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis // Eur. J. Clin. Invest. – 1997. – Vol. 27. – Р. 667–672.
45. Xie W., Snyder M. Two short autoepitopes on the nuclear dot antigen are similar to epitopes encoded by the Epstein-Barr virus // PNAS. – 1995. – Vol. 92, N 5. – Р. 1639–1643.
Review
For citations:
Sheptulina A.F., Mayevskaya M.V., Ivashkin V.T. Critical evaluation of pathogenic factors of primary biliary cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(3):39-48. (In Russ.)
Views:
109
Email this article 
